Function Sponsored by
Atrium Biotechnologies has announced the creation of a tri-peptide linked to a lipid for optimal penetration and efficacy in reducing inflammation and redness. Neutrazen was designed by the company to soothe irritated skin and maintain and restore a normal skin sensitivity threshold.
The company reported that an in vivo study found the ingredient to bind and activate the melanocortin-1 receptor (MC1-R) to modulate the production of UVB-induced inflammatory cytokines such as interleukin-8 (IL-8). An ex vivo study reportedly revealed the peptide to inhibit TNF-α production and prevent edema formation and vasodilation in a cutaneous model of neurogenic inflammation.
According to the company, the ingredient calmed irritation, redness and swelling. Furthermore, it was found to both prevent and reverse the signs of chemical-induced neurogenic inflammation.
The anti-irritant is recommended for formulation into baby care products; soothing care; daily protective care; sensitive and intolerant skin formulations; after-sun care; soothing care for atopic dermatitis, contact dermatitis, eczema, rosacea; and soothing care for skin stressed by micro-dermabrasion, AHA and laser treatments, chemical peels, anti-acne therapies and dermatological surgeries.
For more information, visit the company's Web site.